Tvardi Therapeutics, Inc. (TVRD)
NASDAQ: TVRD · Real-Time Price · USD
27.86
+2.41 (9.47%)
May 2, 2025, 4:00 PM EDT - Market closed
Tvardi Therapeutics Stock Forecast
Stock Price Forecast
The 1 analyst with a 12-month price forecast for Tvardi Therapeutics stock has a target of 39, which predicts an increase of 39.99% from the current stock price of 27.86.
Analyst Consensus: Strong Buy
Analyst Ratings
According to 1 stock analyst, the rating for Tvardi Therapeutics is "Strong Buy". This means that the analyst believes this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '25 |
|---|---|
| Strong Buy | 1 |
| Buy | 0 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 1 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Jones Trading | Jones Trading | Strong Buy Initiates $39 | Strong Buy | Initiates | $39 | +39.99% | Apr 28, 2025 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
n/a
EPS Next Year
n/a
No financial forecasts available for this stock
Revenue Forecast
| Revenue | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|---|
| High | 23.0M | 141.7M | 31.6M | ||||||
| Avg | 20.5M | 67.0M | 23.8M | ||||||
| Low | 14.9M | 24.8M | 21.6M |
Revenue Growth
| Revenue Growth | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| High | 590.6% | -52.9% | 150.7% | |||||
| Avg | 226.7% | -64.5% | 129.2% | |||||
| Low | 20.7% | -67.8% | 87.9% |
EPS Forecast
| EPS | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|---|
| High | -86.18 | 8.69 | -57.83 | ||||||
| Avg | -93.72 | -44.66 | -58.90 | ||||||
| Low | -96.31 | -81.50 | -61.03 |
EPS Growth
| EPS Growth | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|---|
| High | - | - | - | |||||
| Avg | - | - | - | |||||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.